Patents by Inventor Michael Schraemi

Michael Schraemi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody specifically binding to insulin-like growth factor-1
    Patent number: 10301383
    Abstract: Isolated antibodies that specifically bind to an epitope comprised in the stretch of amino acids ranging from amino acid 76 to amino acid 84 of human insulin-like growth factor-1 precursor (SEQ ID NO:1). Use of the novel antibodies for the sensitive and specific detection of insulin-like growth factor-1, in some embodiments while in the presence of high excess concentration of insulin-like growth factor-2, for example in a bodily fluid sample.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: May 28, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Herbert Andres, Hartmut Duefel, Michael Gerg, Frank Kowalewsky, Christian Scholz, Michael Schraemi
  • DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT
    Publication number: 20170275380
    Abstract: A bivalent binding agent, capable of binding a polypeptide dimer, consisting of two monovalent binders linked to each other via a linker, the first monovalent binder binds an epitope of a first target polypeptide comprised in said dimer and the second monovalent binder binds to an epitope of a second target polypeptide comprised in said dimer. Each monovalent binder has a Kdiss in the range of 5×10?3/sec to 10?4/sec, and the bivalent binding agent has a Kdiss of 3×10?5/sec or less. Methods of making and using such bivalent binding agent in histological staining procedures are also disclosed.
    Type: Application
    Filed: March 21, 2017
    Publication date: September 28, 2017
    Inventors: Michael Gerg, Dieter Heindl, Alfred Mertens, Christoph Rutz, Michael Schraemi, Monika Soukupova, Claudio Sustmann, Michael Tacke, Jan van Dieck
  • DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BIVALENT BINDING AGENT
    Publication number: 20170275381
    Abstract: A bivalent binding agent having a first monovalent binder that binds to a polypeptide epitope of a target polypeptide, a second monovalent binder that binds to a posttranslational polypeptide modification on the target polypeptide and a linker. Further disclosed are methods for the detection of a posttranslationally modified target polypeptide, for making the disclosed bivalent binding agent, and for use of the disclosed bivalent binding agent in histological staining procedures.
    Type: Application
    Filed: March 21, 2017
    Publication date: September 28, 2017
    Inventors: Michael Gerg, Dieter Heindl, Christian Klein, Alfred Mertens, Volker Schmid, Michael Schraemi, Monika Soukupova, Michael Tacke
  • Use of an anti-Tau pS422 antibody for the treatment of brain diseases
    Patent number: 9290567
    Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: March 22, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Bohrmann, Ulrich Goepfert, Fiona Grueninger, Walter Huber, Hans-Willi Krell, Valeria Lifke, Olaf Mundigl, Sonja Offner, Laurence Ozmen, Michael Schraemi
  • USE OF AN ANTI-TAU PS422 ANTIBODY FOR THE TREATMENT OF BRAIN DISEASES
    Publication number: 20130310541
    Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.
    Type: Application
    Filed: June 6, 2013
    Publication date: November 21, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bernd Bohrmann, Ulrich Goepfert, Fiona Grueninger, Walter Huber, Hans-Willi Krell, Valeria Lifke, Olaf Mundigl, Sonja Offner, Laurence Ozmen, Michael Schraemi